Foundation Venture Capital Group

Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, founded in 2009. The company specializes in developing therapeutics for a range of medical conditions, including blood cancers, autoimmune and inflammatory diseases, and HIV. Its lead product, Leukotoxin, is a bacterial toxin that specifically targets and eliminates white blood cells, making it a promising candidate for treating hematologic malignancies such as leukemia and lymphoma. In addition to its primary focus on blood cancers, Actinobac Biomed is exploring the use of Leukotoxin and its derivatives for treating infectious diseases like HIV/AIDS and tuberculosis, as well as various autoimmune disorders, including rheumatoid arthritis and psoriasis. The company is committed to advancing its drug candidates through a strategic approach that prioritizes hematologic malignancies while also fostering early-stage drug discovery programs to maintain a robust pipeline of novel therapeutic agents.

MentiNova, Inc., established in 2012 and headquartered in Piscataway, New Jersey, specializes in developing an oral medication aimed at treating symptoms of Parkinson’s disease. The company focuses on creating drugs that address neurodegenerative disorders and mental diseases, thereby enhancing the quality of life for patients by providing effective treatment options to healthcare providers.

GeneAssess, Inc. is a New Jersey-based biotechnology company that is working to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging. The FRY gene appears to be found in the breast cancer model but also shows potential for other cancers. In research performed to date, mutations in the gene increase rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models. GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY. The company has an exclusive license to the intellectual property developed by Dr. Zarbl.

Affineti Biologics is a New Jersey-based company that develops plaque-reducing dental hygiene products.

Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, founded in 2009. The company specializes in developing therapeutics for a range of medical conditions, including blood cancers, autoimmune and inflammatory diseases, and HIV. Its lead product, Leukotoxin, is a bacterial toxin that specifically targets and eliminates white blood cells, making it a promising candidate for treating hematologic malignancies such as leukemia and lymphoma. In addition to its primary focus on blood cancers, Actinobac Biomed is exploring the use of Leukotoxin and its derivatives for treating infectious diseases like HIV/AIDS and tuberculosis, as well as various autoimmune disorders, including rheumatoid arthritis and psoriasis. The company is committed to advancing its drug candidates through a strategic approach that prioritizes hematologic malignancies while also fostering early-stage drug discovery programs to maintain a robust pipeline of novel therapeutic agents.

Snowdon, Inc. is a biopharmaceutical company based in Princeton, New Jersey, founded in 2005. It is dedicated to the discovery and development of innovative small-molecule therapeutics targeting pain, infectious diseases, and neurological disorders. The company's pipeline includes several promising candidates, such as SND-121, a preclinical compound designed to treat neuropathic pain, SND-159 for tuberculosis, and SND-226 for toxoplasmosis. Additionally, Snowdon is engaged in early-stage discovery projects focused on developing new treatments for neurological conditions, including Fragile X Syndrome, a leading cause of autism and related behaviors. The company aims to address significant medical needs by offering safe and effective therapies and has expertise in both the development of new chemical entities and the repurposing of existing drugs for new clinical applications.